Trials / Completed
CompletedNCT01247571
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with uterine cancer that has come back or has not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of uterine cancer by blocking blood flow to the tumor.
Detailed description
PRIMARY OBJECTIVES: I. To assess the activity of pazopanib in patients with persistent or recurrent carcinosarcoma of the uterus as measured by the proportion of patients who survive progression-free for at least 6 months and the proportion of patients who have objective tumor response (complete or partial). SECONDARY OBJECTIVES: I. To determine the frequency and severity of adverse events as assessed by Common Terminology Criteria of Adverse Events version 4.0 (CTCAE v4.0). II. To determine the duration of progression-free survival and overall survival. OUTLINE: This is a multicenter study. Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib Hydrochloride | Given PO |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2010-11-24
- Last updated
- 2019-08-08
- Results posted
- 2017-07-27
Locations
41 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01247571. Inclusion in this directory is not an endorsement.